申请人:Novartis AG
公开号:US06051577A1
公开(公告)日:2000-04-18
There are described pyrrolo[2,3]pyrimidines of formula I ##STR1## wherein R.sub.1 -R.sub.5, m and n are as defined in the description. The compounds have valuable pharmaceutical properties and are effective especially as tyrosine protein kinase inhibitors. They can be used in the treatment of bone diseases and other diseases in warm-blooded animals that can be favorably influenced by the inhibition of tyrosine protein kinase.
描述了化学式I的吡咯并[2,3]嘧啶,其中R.sub.1 -R.sub.5,m和n如描述中所定义。这些化合物具有有价值的药理特性,尤其作为酪氨酸蛋白激酶抑制剂效果显著。它们可用于治疗骨疾病和其他受酪氨酸蛋白激酶抑制有利影响的温血动物的疾病。